E
BetterLife Pharma Inc.
BETRF
$0.055
-$0.009-14.06%
E
Sell
3/28/2025Downgrade
BetterLife Pharma Inc. (BETRF) was downgraded to E+ from D- on 3/28/2025 due to a decline in the volatility index and total return index.
BetterLife Pharma Inc. (BETRF) was downgraded to E+ from D- on 3/28/2025 due to a decline in the volatility index and total return index.
D
Sell
3/13/2025Upgraded
BetterLife Pharma Inc. (BETRF) was upgraded to D- from E+ on 3/13/2025 due to an increase in the volatility index.
BetterLife Pharma Inc. (BETRF) was upgraded to D- from E+ on 3/13/2025 due to an increase in the volatility index.
E
Sell
2/25/2025Downgrade
BetterLife Pharma Inc. (BETRF) was downgraded to E+ from D- on 2/25/2025 due to a decline in the volatility index.
BetterLife Pharma Inc. (BETRF) was downgraded to E+ from D- on 2/25/2025 due to a decline in the volatility index.
D
Sell
2/6/2025Upgraded
BetterLife Pharma Inc. (BETRF) was upgraded to D- from E+ on 2/6/2025 due to an increase in the volatility index, total return index and growth index.
BetterLife Pharma Inc. (BETRF) was upgraded to D- from E+ on 2/6/2025 due to an increase in the volatility index, total return index and growth index.
E
Sell
1/22/2025Downgrade
BetterLife Pharma Inc. (BETRF) was downgraded to E+ from D- on 1/22/2025 due to a decline in the volatility index.
BetterLife Pharma Inc. (BETRF) was downgraded to E+ from D- on 1/22/2025 due to a decline in the volatility index.
D
Sell
1/7/2025Upgraded
BetterLife Pharma Inc. (BETRF) was upgraded to D- from E+ on 1/7/2025 due to an increase in the volatility index, solvency index and valuation index. Debt to equity declined from -0.1 to -0.11.
BetterLife Pharma Inc. (BETRF) was upgraded to D- from E+ on 1/7/2025 due to an increase in the volatility index, solvency index and valuation index. Debt to equity declined from -0.1 to -0.11.
E
Sell
12/3/2024Downgrade
BetterLife Pharma Inc. (BETRF) was downgraded to E+ from D- on 12/3/2024 due to a decline in the total return index and volatility index.
BetterLife Pharma Inc. (BETRF) was downgraded to E+ from D- on 12/3/2024 due to a decline in the total return index and volatility index.
D
Sell
7/2/2024Upgraded
BetterLife Pharma Inc. (BETRF) was upgraded to D- from E+ on 7/2/2024 due to an increase in the growth index, volatility index and solvency index. The quick ratio increased from 0.01 to 0.07, and debt to equity declined from -0.05 to -0.14.
BetterLife Pharma Inc. (BETRF) was upgraded to D- from E+ on 7/2/2024 due to an increase in the growth index, volatility index and solvency index. The quick ratio increased from 0.01 to 0.07, and debt to equity declined from -0.05 to -0.14.
E
Sell
6/14/2024Downgrade
BetterLife Pharma Inc. (BETRF) was downgraded to E+ from D- on 6/14/2024 due to a major decline in the solvency index, growth index and volatility index. Earnings per share declined from -$0.0013 to -$0.0084, the quick ratio declined from 0.02 to 0.01, and EBIT declined 5.13% from -$514.5 to -$540.9.
BetterLife Pharma Inc. (BETRF) was downgraded to E+ from D- on 6/14/2024 due to a major decline in the solvency index, growth index and volatility index. Earnings per share declined from -$0.0013 to -$0.0084, the quick ratio declined from 0.02 to 0.01, and EBIT declined 5.13% from -$514.5 to -$540.9.
D
Sell
5/30/2024Upgraded
BetterLife Pharma Inc. (BETRF) was upgraded to D- from E+ on 5/30/2024 due to an increase in the total return index and volatility index.
BetterLife Pharma Inc. (BETRF) was upgraded to D- from E+ on 5/30/2024 due to an increase in the total return index and volatility index.
E
Sell
5/15/2024Downgrade
BetterLife Pharma Inc. (BETRF) was downgraded to E+ from D- on 5/15/2024 due to a decline in the volatility index and valuation index.
BetterLife Pharma Inc. (BETRF) was downgraded to E+ from D- on 5/15/2024 due to a decline in the volatility index and valuation index.
D
Sell
4/29/2024Upgraded
BetterLife Pharma Inc. (BETRF) was upgraded to D- from E+ on 4/29/2024 due to an increase in the volatility index and total return index.
BetterLife Pharma Inc. (BETRF) was upgraded to D- from E+ on 4/29/2024 due to an increase in the volatility index and total return index.
E
Sell
3/19/2024Downgrade
BetterLife Pharma Inc. (BETRF) was downgraded to E+ from D- on 3/19/2024 due to a decline in the volatility index, total return index and valuation index.
BetterLife Pharma Inc. (BETRF) was downgraded to E+ from D- on 3/19/2024 due to a decline in the volatility index, total return index and valuation index.
D
Sell
3/1/2024Upgraded
BetterLife Pharma Inc. (BETRF) was upgraded to D- from E+ on 3/1/2024 due to a major increase in the solvency index, growth index and total return index. Earnings per share increased from -$0.0075 to -$0.0013, the quick ratio increased from 0.01 to 0.02, and EBIT increased 32.35% from -$760.5 to -$514.5.
BetterLife Pharma Inc. (BETRF) was upgraded to D- from E+ on 3/1/2024 due to a major increase in the solvency index, growth index and total return index. Earnings per share increased from -$0.0075 to -$0.0013, the quick ratio increased from 0.01 to 0.02, and EBIT increased 32.35% from -$760.5 to -$514.5.
E
Sell
3/14/2023Downgrade
BetterLife Pharma Inc. (BETRF) was downgraded to E+ from D- on 3/14/2023 due to a decline in the volatility index and total return index.
BetterLife Pharma Inc. (BETRF) was downgraded to E+ from D- on 3/14/2023 due to a decline in the volatility index and total return index.
D
Sell
2/23/2023Upgraded
BetterLife Pharma Inc. (BETRF) was upgraded to D- from E+ on 2/23/2023 due to an increase in the total return index.
BetterLife Pharma Inc. (BETRF) was upgraded to D- from E+ on 2/23/2023 due to an increase in the total return index.
E
Sell
2/8/2023Downgrade
BetterLife Pharma Inc. (BETRF) was downgraded to E+ from D- on 2/8/2023 due to a decline in the volatility index.
BetterLife Pharma Inc. (BETRF) was downgraded to E+ from D- on 2/8/2023 due to a decline in the volatility index.
D
Sell
12/23/2022Downgrade
BetterLife Pharma Inc. (BETRF) was downgraded to D- from D on 12/23/2022 due to a large decline in the growth index and solvency index. Earnings per share declined from -$0.0102 to -$0.0376, EBIT declined 247.17% from -$940.6 to -$3.27M, and operating cash flow declined 88.05% from -$253.5 to -$476.7.
BetterLife Pharma Inc. (BETRF) was downgraded to D- from D on 12/23/2022 due to a large decline in the growth index and solvency index. Earnings per share declined from -$0.0102 to -$0.0376, EBIT declined 247.17% from -$940.6 to -$3.27M, and operating cash flow declined 88.05% from -$253.5 to -$476.7.
D
Sell
8/29/2022Upgraded
BetterLife Pharma Inc. (BETRF) was upgraded to D from D- on 8/29/2022 due to an increase in the volatility index and total return index.
BetterLife Pharma Inc. (BETRF) was upgraded to D from D- on 8/29/2022 due to an increase in the volatility index and total return index.
D
Sell
8/12/2022Downgrade
BetterLife Pharma Inc. (BETRF) was downgraded to D- from D on 8/12/2022 due to a decline in the volatility index.
BetterLife Pharma Inc. (BETRF) was downgraded to D- from D on 8/12/2022 due to a decline in the volatility index.
D
Sell
7/25/2022Upgraded
BetterLife Pharma Inc. (BETRF) was upgraded to D from D- on 7/25/2022 due to a noticeable increase in the growth index, volatility index and solvency index. Operating cash flow increased 79.35% from -$1.54M to -$317.6, and earnings per share increased from -$0.0365 to -$0.0316.
BetterLife Pharma Inc. (BETRF) was upgraded to D from D- on 7/25/2022 due to a noticeable increase in the growth index, volatility index and solvency index. Operating cash flow increased 79.35% from -$1.54M to -$317.6, and earnings per share increased from -$0.0365 to -$0.0316.
D
Sell
6/24/2022Upgraded
BetterLife Pharma Inc. (BETRF) was upgraded to D- from E+ on 6/24/2022 due to an increase in the volatility index.
BetterLife Pharma Inc. (BETRF) was upgraded to D- from E+ on 6/24/2022 due to an increase in the volatility index.
E
Sell
6/8/2022Downgrade
BetterLife Pharma Inc. (BETRF) was downgraded to E+ from D- on 6/8/2022 due to a major decline in the solvency index, growth index and valuation index. Debt to equity increased from -0.42 to -0.08, the quick ratio declined from 0.6 to 0.12, and earnings per share declined from -$0.0239 to -$0.0365.
BetterLife Pharma Inc. (BETRF) was downgraded to E+ from D- on 6/8/2022 due to a major decline in the solvency index, growth index and valuation index. Debt to equity increased from -0.42 to -0.08, the quick ratio declined from 0.6 to 0.12, and earnings per share declined from -$0.0239 to -$0.0365.
D
Sell
6/1/2022Downgrade
BetterLife Pharma Inc. (BETRF) was downgraded to D- from D on 6/1/2022 due to a decline in the volatility index.
BetterLife Pharma Inc. (BETRF) was downgraded to D- from D on 6/1/2022 due to a decline in the volatility index.
D
Sell
5/16/2022Upgraded
BetterLife Pharma Inc. (BETRF) was upgraded to D from E+ on 05/16/2022.
BetterLife Pharma Inc. (BETRF) was upgraded to D from E+ on 05/16/2022.
E
Sell
5/13/2022Downgrade
BetterLife Pharma Inc. (BETRF) was downgraded to E+ from D on 05/13/2022.
BetterLife Pharma Inc. (BETRF) was downgraded to E+ from D on 05/13/2022.
D
Sell
5/4/2022Upgraded
BetterLife Pharma Inc. (BETRF) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index.
BetterLife Pharma Inc. (BETRF) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index.
E
Sell
5/1/2022Downgrade
BetterLife Pharma Inc. (BETRF) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index and total return index.
BetterLife Pharma Inc. (BETRF) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index and total return index.
D
Sell
4/21/2022Upgraded
BetterLife Pharma Inc. (BETRF) was upgraded to D from E+ on 04/21/2022.
BetterLife Pharma Inc. (BETRF) was upgraded to D from E+ on 04/21/2022.
E
Sell
4/20/2022Downgrade
BetterLife Pharma Inc. (BETRF) was downgraded to E+ from D on 04/20/2022.
BetterLife Pharma Inc. (BETRF) was downgraded to E+ from D on 04/20/2022.
D
Sell
4/18/2022Upgraded
BetterLife Pharma Inc. (BETRF) was upgraded to D from D- on 4/18/2022 due to an increase in the volatility index.
BetterLife Pharma Inc. (BETRF) was upgraded to D from D- on 4/18/2022 due to an increase in the volatility index.
D
Sell
3/21/2022Downgrade
BetterLife Pharma Inc. (BETRF) was downgraded to D- from D on 3/21/2022 due to a decline in the volatility index and total return index.
BetterLife Pharma Inc. (BETRF) was downgraded to D- from D on 3/21/2022 due to a decline in the volatility index and total return index.
D
Sell
3/2/2022Upgraded
BetterLife Pharma Inc. (BETRF) was upgraded to D from D- on 3/2/2022 due to an increase in the volatility index.
BetterLife Pharma Inc. (BETRF) was upgraded to D from D- on 3/2/2022 due to an increase in the volatility index.
D
Sell
2/11/2022Downgrade
BetterLife Pharma Inc. (BETRF) was downgraded to D- from D on 2/11/2022 due to a decline in the volatility index and total return index.
BetterLife Pharma Inc. (BETRF) was downgraded to D- from D on 2/11/2022 due to a decline in the volatility index and total return index.
D
Sell
12/20/2021Upgraded
BetterLife Pharma Inc. (BETRF) was upgraded to D from E+ on 12/20/2021 due to a major increase in the growth index, valuation index and total return index. Operating cash flow increased 51.12% from -$3.47M to -$1.69M, earnings per share increased from -$0.0407 to -$0.0239, and EBIT increased 38.74% from -$2.73M to -$1.68M.
BetterLife Pharma Inc. (BETRF) was upgraded to D from E+ on 12/20/2021 due to a major increase in the growth index, valuation index and total return index. Operating cash flow increased 51.12% from -$3.47M to -$1.69M, earnings per share increased from -$0.0407 to -$0.0239, and EBIT increased 38.74% from -$2.73M to -$1.68M.
E
Sell
9/28/2021Downgrade
BetterLife Pharma Inc. (BETRF) was downgraded to E+ from D- on 9/28/2021 due to a decline in the valuation index, growth index and total return index. Operating cash flow declined 52.47% from -$2.27M to -$3.47M, EBIT declined 45.2% from -$1.88M to -$2.73M, and earnings per share declined from -$0.0356 to -$0.0407.
BetterLife Pharma Inc. (BETRF) was downgraded to E+ from D- on 9/28/2021 due to a decline in the valuation index, growth index and total return index. Operating cash flow declined 52.47% from -$2.27M to -$3.47M, EBIT declined 45.2% from -$1.88M to -$2.73M, and earnings per share declined from -$0.0356 to -$0.0407.
D
Sell
6/2/2021Upgraded
BetterLife Pharma Inc. (BETRF) was upgraded to D- from E+ on 6/2/2021 due to an increase in the valuation index, growth index and volatility index. EBIT increased 15.06% from -$2.11M to -$1.79M.
BetterLife Pharma Inc. (BETRF) was upgraded to D- from E+ on 6/2/2021 due to an increase in the valuation index, growth index and volatility index. EBIT increased 15.06% from -$2.11M to -$1.79M.
E
Sell
5/6/2021Downgrade
BetterLife Pharma Inc. (BETRF) was downgraded to E+ from D- on 5/6/2021 due to a decline in the volatility index.
BetterLife Pharma Inc. (BETRF) was downgraded to E+ from D- on 5/6/2021 due to a decline in the volatility index.
D
Sell
2/25/2021Upgraded
BetterLife Pharma Inc. (BETRF) was upgraded to D- from E+ on 2/25/2021 due to an increase in the total return index, volatility index and valuation index.
BetterLife Pharma Inc. (BETRF) was upgraded to D- from E+ on 2/25/2021 due to an increase in the total return index, volatility index and valuation index.
E
Sell
12/31/2020Downgrade
BetterLife Pharma Inc. (BETRF) was downgraded to E+ from D- on 12/31/2020 due to a noticeable decline in the growth index, total return index and volatility index. Operating cash flow declined 241% from -$550 to -$1.88M, earnings per share declined from -$0.0663 to -$0.1882, and EBIT declined 84.73% from -$1.14M to -$2.11M.
BetterLife Pharma Inc. (BETRF) was downgraded to E+ from D- on 12/31/2020 due to a noticeable decline in the growth index, total return index and volatility index. Operating cash flow declined 241% from -$550 to -$1.88M, earnings per share declined from -$0.0663 to -$0.1882, and EBIT declined 84.73% from -$1.14M to -$2.11M.
D
Sell
10/12/2020Downgrade
BetterLife Pharma Inc. (BETRF) was downgraded to D- from D on 10/12/2020 due to a decline in the total return index, solvency index and growth index. Earnings per share declined from $0.0028 to -$0.0663, the quick ratio declined from 1.94 to 1.45, and EBIT declined 17.23% from -$975.6 to -$1.14M.
BetterLife Pharma Inc. (BETRF) was downgraded to D- from D on 10/12/2020 due to a decline in the total return index, solvency index and growth index. Earnings per share declined from $0.0028 to -$0.0663, the quick ratio declined from 1.94 to 1.45, and EBIT declined 17.23% from -$975.6 to -$1.14M.
D
Sell
7/6/2020Upgraded
BetterLife Pharma Inc. (BETRD) was upgraded to D from D- on 7/6/2020 due to a noticeable increase in the growth index, total return index and solvency index. Earnings per share increased from -$0.4724 to $0.0145, debt to equity declined from 0.03 to 0, and operating cash flow increased 14.12% from -$1.08M to -$925.3.
BetterLife Pharma Inc. (BETRD) was upgraded to D from D- on 7/6/2020 due to a noticeable increase in the growth index, total return index and solvency index. Earnings per share increased from -$0.4724 to $0.0145, debt to equity declined from 0.03 to 0, and operating cash flow increased 14.12% from -$1.08M to -$925.3.
D
Sell
6/2/2020Downgrade
BetterLife Pharma Inc. (PVOTF) was downgraded to D- from D on 6/2/2020 due to a noticeable decline in the growth index, valuation index and solvency index. Earnings per share declined from -$0.0114 to -$0.0472, debt to equity increased from 0.01 to 0.03, and the quick ratio declined from 8.22 to 2.94.
BetterLife Pharma Inc. (PVOTF) was downgraded to D- from D on 6/2/2020 due to a noticeable decline in the growth index, valuation index and solvency index. Earnings per share declined from -$0.0114 to -$0.0472, debt to equity increased from 0.01 to 0.03, and the quick ratio declined from 8.22 to 2.94.
D
Sell
5/1/2020Upgraded
BetterLife Pharma Inc. (PVOTF) was upgraded to D from D- on 5/1/2020 due to a noticeable increase in the growth index. Operating cash flow increased 69.66% from -$3.41M to -$1.03M, earnings per share increased from -$0.021 to -$0.0114, and EBIT increased 44.91% from -$3.16M to -$1.74M.
BetterLife Pharma Inc. (PVOTF) was upgraded to D from D- on 5/1/2020 due to a noticeable increase in the growth index. Operating cash flow increased 69.66% from -$3.41M to -$1.03M, earnings per share increased from -$0.021 to -$0.0114, and EBIT increased 44.91% from -$3.16M to -$1.74M.
D
Sell
11/15/2019Downgrade
Pivot Pharmaceuticals Inc. (PVOTF) was downgraded to D- from D on 11/15/2019 due to a noticeable decline in the total return index.
Pivot Pharmaceuticals Inc. (PVOTF) was downgraded to D- from D on 11/15/2019 due to a noticeable decline in the total return index.
D
Sell
10/4/2019Upgraded
Pivot Pharmaceuticals Inc. (PVOTF) was upgraded to D from D- on 10/4/2019 due to a substantial increase in the solvency index, total return index and valuation index. The quick ratio increased from 0.02 to 13.17, and debt to equity declined from 0.95 to 0.01.
Pivot Pharmaceuticals Inc. (PVOTF) was upgraded to D from D- on 10/4/2019 due to a substantial increase in the solvency index, total return index and valuation index. The quick ratio increased from 0.02 to 13.17, and debt to equity declined from 0.95 to 0.01.
D
Sell
4/1/2019Downgrade
Pivot Pharmaceuticals Inc. (PVOTF) was downgraded to D- from D on 4/1/2019 due to a decline in the total return index.
Pivot Pharmaceuticals Inc. (PVOTF) was downgraded to D- from D on 4/1/2019 due to a decline in the total return index.
D
Sell
2/26/2019Upgraded
Pivot Pharmaceuticals Inc. (PVOTF) was upgraded to D from D- on 2/26/2019 due to an increase in the valuation index.
Pivot Pharmaceuticals Inc. (PVOTF) was upgraded to D from D- on 2/26/2019 due to an increase in the valuation index.
D
Sell
2/11/2019Downgrade
Pivot Pharmaceuticals Inc. (PVOTF) was downgraded to D- from D on 2/11/2019 due to a significant decline in the total return index, growth index and efficiency index. Earnings per share declined from -$0.0166 to -$0.04, net income declined 138.79% from -$1.41M to -$3.38M, and EBIT declined 19.07% from -$1.16M to -$1.38M.
Pivot Pharmaceuticals Inc. (PVOTF) was downgraded to D- from D on 2/11/2019 due to a significant decline in the total return index, growth index and efficiency index. Earnings per share declined from -$0.0166 to -$0.04, net income declined 138.79% from -$1.41M to -$3.38M, and EBIT declined 19.07% from -$1.16M to -$1.38M.
D
Sell
12/15/2017Downgrade
Pivot Pharmaceuticals Inc. (PVOTF) was downgraded to D from D+ on 12/15/2017 due to a noticeable decline in the valuation index, efficiency index and growth index. Operating cash flow declined 15.9% from -$61 to -$70.7.
Pivot Pharmaceuticals Inc. (PVOTF) was downgraded to D from D+ on 12/15/2017 due to a noticeable decline in the valuation index, efficiency index and growth index. Operating cash flow declined 15.9% from -$61 to -$70.7.
D
Sell
10/5/2017Upgraded
Pivot Pharmaceuticals Inc. (PVOTF) was upgraded to D+ from D on 10/5/2017 due to an increase in the total return index and volatility index.
Pivot Pharmaceuticals Inc. (PVOTF) was upgraded to D+ from D on 10/5/2017 due to an increase in the total return index and volatility index.
D
Sell
9/15/2017Downgrade
Pivot Pharmaceuticals Inc. (PVOTF) was downgraded to D from C- on 9/15/2017 due to a significant decline in the efficiency index, valuation index and solvency index. The quick ratio declined from 0.03 to 0.01.
Pivot Pharmaceuticals Inc. (PVOTF) was downgraded to D from C- on 9/15/2017 due to a significant decline in the efficiency index, valuation index and solvency index. The quick ratio declined from 0.03 to 0.01.
C
Hold
4/28/2017Upgraded
Pivot Pharmaceuticals Inc. (PVOTF) was upgraded to C- from D on 4/28/2017 due to a significant increase in the efficiency index and growth index. Operating cash flow increased 37.27% from -$161.8 to -$101.5, earnings per share increased from -$0.0126 to -$0.0107, and net income increased 14.95% from -$954.9 to -$812.1.
Pivot Pharmaceuticals Inc. (PVOTF) was upgraded to C- from D on 4/28/2017 due to a significant increase in the efficiency index and growth index. Operating cash flow increased 37.27% from -$161.8 to -$101.5, earnings per share increased from -$0.0126 to -$0.0107, and net income increased 14.95% from -$954.9 to -$812.1.
D
Sell
9/13/2016Downgrade
Pivot Pharmaceuticals Inc. (PVOTF) was downgraded to D from D+ on 9/13/2016 due to a significant decline in the efficiency index, solvency index and total return index. The quick ratio declined from 0.05 to 0, and total capital declined 38.42% from -$508.9 to -$704.4.
Pivot Pharmaceuticals Inc. (PVOTF) was downgraded to D from D+ on 9/13/2016 due to a significant decline in the efficiency index, solvency index and total return index. The quick ratio declined from 0.05 to 0, and total capital declined 38.42% from -$508.9 to -$704.4.
D
Sell
7/11/2016Downgrade
Pivot Pharmaceuticals Inc. (PVOTF) was downgraded to D+ from C- on 7/11/2016 due to a decline in the total return index and volatility index.
Pivot Pharmaceuticals Inc. (PVOTF) was downgraded to D+ from C- on 7/11/2016 due to a decline in the total return index and volatility index.
C
Hold
6/24/2016Upgraded
Pivot Pharmaceuticals Inc. (PVOTF) was upgraded to C- from E+ on 6/24/2016 due to a significant increase in the efficiency index, solvency index and growth index.
Pivot Pharmaceuticals Inc. (PVOTF) was upgraded to C- from E+ on 6/24/2016 due to a significant increase in the efficiency index, solvency index and growth index.
E
Sell
6/15/2016Downgrade
Pivot Pharmaceuticals Inc. (PVOTF) was downgraded to E+ from D on 6/15/2016 due to a significant decline in the efficiency index, solvency index and valuation index. The quick ratio declined from 0.16 to 0.05.
Pivot Pharmaceuticals Inc. (PVOTF) was downgraded to E+ from D on 6/15/2016 due to a significant decline in the efficiency index, solvency index and valuation index. The quick ratio declined from 0.16 to 0.05.
D
Sell
5/20/2016Downgrade
Pivot Pharmaceuticals Inc. (PVOTF) was downgraded to D from D+ on 5/20/2016 due to a decline in the volatility index.
Pivot Pharmaceuticals Inc. (PVOTF) was downgraded to D from D+ on 5/20/2016 due to a decline in the volatility index.
D
Sell
5/5/2016Upgraded
Pivot Pharmaceuticals Inc. (PVOTF) was upgraded to D+ from D on 5/5/2016 due to a significant increase in the efficiency index and valuation index.
Pivot Pharmaceuticals Inc. (PVOTF) was upgraded to D+ from D on 5/5/2016 due to a significant increase in the efficiency index and valuation index.
D
Sell
3/11/2016Downgrade
Pivot Pharmaceuticals Inc. (PVOTF) was downgraded to D from D+ on 3/11/2016 due to a significant decline in the volatility index and total return index.
Pivot Pharmaceuticals Inc. (PVOTF) was downgraded to D from D+ on 3/11/2016 due to a significant decline in the volatility index and total return index.
D
Sell
9/11/2015Downgrade
Pivot Pharmaceuticals Inc. (PVOTF) was downgraded to D+ from C on 9/11/2015 due to a significant decline in the efficiency index, valuation index and growth index. Total capital declined 379.39% from -$49.5 to $138.3.
Pivot Pharmaceuticals Inc. (PVOTF) was downgraded to D+ from C on 9/11/2015 due to a significant decline in the efficiency index, valuation index and growth index. Total capital declined 379.39% from -$49.5 to $138.3.
C
Hold
1/12/2015Downgrade
Neurokine Pharmaceuticals Inc. (NEUKF) was downgraded to C from C+ on 1/12/2015 due to a substantial decline in the volatility index.
Neurokine Pharmaceuticals Inc. (NEUKF) was downgraded to C from C+ on 1/12/2015 due to a substantial decline in the volatility index.
C
Hold
12/26/2014Upgraded
Neurokine Pharmaceuticals Inc. (NEUKF) was upgraded to C+ from C on 12/26/2014 due to a substantial increase in the valuation index, growth index and efficiency index. Net income increased 350.15% from -$33.7 to -$151.7, earnings per share increased from -$0.0003 to -$0.0013, and total capital increased 52.25% from -$220.1 to -$335.1.
Neurokine Pharmaceuticals Inc. (NEUKF) was upgraded to C+ from C on 12/26/2014 due to a substantial increase in the valuation index, growth index and efficiency index. Net income increased 350.15% from -$33.7 to -$151.7, earnings per share increased from -$0.0003 to -$0.0013, and total capital increased 52.25% from -$220.1 to -$335.1.
C
Hold
10/10/2014Downgrade
Neurokine Pharmaceuticals Inc. (NEUKF) was downgraded to C from C+ on 10/10/2014 due to a substantial decline in the valuation index.
Neurokine Pharmaceuticals Inc. (NEUKF) was downgraded to C from C+ on 10/10/2014 due to a substantial decline in the valuation index.
C
Hold
9/22/2014Upgraded
Neurokine Pharmaceuticals Inc. (NEUKF) was upgraded to C+ from C on 9/22/2014 due to a large increase in the volatility index, growth index and efficiency index. EBIT increased 165.38% from -$10.4 to -$27.6, and total capital increased 14.16% from -$192.8 to -$220.1.
Neurokine Pharmaceuticals Inc. (NEUKF) was upgraded to C+ from C on 9/22/2014 due to a large increase in the volatility index, growth index and efficiency index. EBIT increased 165.38% from -$10.4 to -$27.6, and total capital increased 14.16% from -$192.8 to -$220.1.
C
Hold
9/5/2014Upgraded
Neurokine Pharmaceuticals Inc. (NEUKF) was upgraded to C from C- on 9/5/2014 due to a substantial increase in the valuation index, volatility index and total return index.
Neurokine Pharmaceuticals Inc. (NEUKF) was upgraded to C from C- on 9/5/2014 due to a substantial increase in the valuation index, volatility index and total return index.
C
Hold
6/17/2014Upgraded
Neurokine Pharmaceuticals Inc. (NEUKF) was upgraded to C- from D+ on 6/17/2014 due to a significant increase in the efficiency index and solvency index. The quick ratio increased from 0.01 to 0.01.
Neurokine Pharmaceuticals Inc. (NEUKF) was upgraded to C- from D+ on 6/17/2014 due to a significant increase in the efficiency index and solvency index. The quick ratio increased from 0.01 to 0.01.
D
Sell
5/16/2014Downgrade
Neurokine Pharmaceuticals Inc. (NEUKF) was downgraded to D+ from C- on 5/16/2014 due to a significant decline in the efficiency index and volatility index. Net income declined 91.1% from -$580 to -$51.6, and total capital declined 27.57% from -$506.4 to -$366.8.
Neurokine Pharmaceuticals Inc. (NEUKF) was downgraded to D+ from C- on 5/16/2014 due to a significant decline in the efficiency index and volatility index. Net income declined 91.1% from -$580 to -$51.6, and total capital declined 27.57% from -$506.4 to -$366.8.
C
Hold
3/24/2014Downgrade
Neurokine Pharmaceuticals Inc. (NEUKF) was downgraded to C- from C on 3/24/2014 due to a substantial decline in the volatility index and valuation index.
Neurokine Pharmaceuticals Inc. (NEUKF) was downgraded to C- from C on 3/24/2014 due to a substantial decline in the volatility index and valuation index.
C
Hold
3/6/2014Upgraded
Neurokine Pharmaceuticals Inc. (NEUKF) was upgraded to C from C- on 3/6/2014 due to a substantial increase in the volatility index, valuation index and growth index.
Neurokine Pharmaceuticals Inc. (NEUKF) was upgraded to C from C- on 3/6/2014 due to a substantial increase in the volatility index, valuation index and growth index.
OTC PK
04/04/2025 10:12AM Eastern
Quotes delayed
